Martindale Pharma agrees takeover of Viridian Pharma

Martindale Pharma has announced the acquisition of Viridian Pharma, a deal that will expand its portfolio of hospital-initiated medicines.

Viridian Pharma is a UK-based developer and supplier of niche pharmaceutical products with a focus on neonatology and paediatrics. It has developed five first-to-market specialty hospital-prescribed medicines, all of which are approved for sale in the UK.

These include treatments for apnoea of prematurity in preterm babies, hypernatremia in infants and respiratory complications in women undergoing caesarean sections, as well as a peppermint water product for symptomatic relief of minor upper digestive complaints.

Martindale Pharma has been working with Viridian Pharma to market some of these products with great success, with the deal expected to support the company's further growth.

Michael Harris, chief executive officer of Martindale Pharma, said: "Viridian has created a portfolio of valuable products which are a very good fit for our hospital-initiated medicines portfolio."

This will strengthen Martindale Pharma's status as a key strategic partner to the NHS and other healthcare providers. It currently supplies more than 100 licensed products in the UK.